Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. HCM
stocks logo

HCM

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
2 Analyst Rating
up Image0
Wall Street analysts forecast HCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HCM is 20.85 USD with a low forecast of 14.70 USD and a high forecast of 27.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
up Image0
Current: 15.570
sliders
Low
14.70
Averages
20.85
High
27.00
up Image0
Current: 15.570
sliders
Low
14.70
Averages
20.85
High
27.00
HSBC
Buy
to
Hold
downgrade
$14.70
2025-05-13
Reason
HSBC
Price Target
$14.70
2025-05-13
downgrade
Buy
to
Hold
Reason
HSBC downgraded Hutchmed to Hold from Buy with a $14.70 price target.
Goldman Sachs
Paul Choi
Hold
Maintains
$17 → $19
2024-08-01
Reason
Goldman Sachs
Paul Choi
Price Target
$17 → $19
2024-08-01
Maintains
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for HUTCHMED (China) Ltd (HCM.O) is 22.50, compared to its 5-year average forward P/E of 20.09. For a more detailed relative valuation and DCF analysis to assess HUTCHMED (China) Ltd 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
20.09
Current PE
22.50
Overvalued PE
363.04
Undervalued PE
-322.85

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-29.48
Current EV/EBITDA
-131.58
Overvalued EV/EBITDA
2.87
Undervalued EV/EBITDA
-61.84

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
5.71
Current PS
3.87
Overvalued PS
9.83
Undervalued PS
1.59

Financials

Annual
Quarterly

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

HCM News & Events

Events Timeline

(ET)
2025-06-30
05:07:48
Hutchmed announces approval of NDA for Orpathys, Tagrisso combination in China
select
2025-06-04 (ET)
2025-06-04
19:54:22
Hutchmed, Innovent jointly announce NDA acceptance in China
select
2025-03-21 (ET)
2025-03-21
06:05:39
Hutchmed says NDA for Tazverik granted conditional approval in China
select
Sign Up For More Events
Sign Up For More Events

News

Preview
2.0
07-04NASDAQ.COM
HUTCHMED Breaks Above 200-Day Moving Average - Bullish for HCM

  • Stock Performance Overview: HCM's stock has a 52-week low of $11.505 and a high of $21.50, with the last trade recorded at $15.82.

  • Author's Perspective Disclaimer: The opinions expressed in the article are solely those of the author and do not necessarily represent Nasdaq, Inc.

Preview
9.5
07-03Newsfilter
HUTCHMED to Announce 2025 Half-Year Financial Results

  • Interim Results Announcement: HUTCHMED will announce its interim results for the six months ending June 30, 2025, on August 7, 2025, with webcasts in English and Chinese for analysts and investors to discuss the results.

  • Company Overview: HUTCHMED is a biopharmaceutical company focused on developing targeted therapies and immunotherapies for cancer and immunological diseases, with several medicines marketed globally.

Preview
9.0
06-30NASDAQ.COM
HUTCHMED and AstraZeneca Announce NMPA Approval of ORPATHYS® and TAGRISSO® Combination for Advanced Lung Cancer Treatment

  • Approval Announcement: HUTCHMED has received approval from the China National Medical Products Administration for its combination therapy of ORPATHYS® and TAGRISSO® to treat advanced lung cancer, demonstrating a 66% reduction in disease progression risk compared to traditional chemotherapy.

  • Significance of Treatment: This combination therapy offers a new all-oral, chemotherapy-free option for patients with EGFR mutation-positive non-small cell lung cancer who have progressed on previous treatments, marking a significant advancement in lung cancer care.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is HUTCHMED (China) Ltd (HCM) stock price today?

The current price of HCM is 15.57 USD — it has increased 0.97 % in the last trading day.

arrow icon

What is HUTCHMED (China) Ltd (HCM)'s business?

HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.

arrow icon

What is the price predicton of HCM Stock?

Wall Street analysts forecast HCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HCM is 20.85 USD with a low forecast of 14.70 USD and a high forecast of 27.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is HUTCHMED (China) Ltd (HCM)'s revenue for the last quarter?

HUTCHMED (China) Ltd revenue for the last quarter amounts to NaN USD, decreased % YoY.

arrow icon

What is HUTCHMED (China) Ltd (HCM)'s earnings per share (EPS) for the last quarter?

HUTCHMED (China) Ltd. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for HUTCHMED (China) Ltd (HCM)'s fundamentals?

The market is revising No Change the revenue expectations for HCM for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 31.84%.
arrow icon

How many employees does HUTCHMED (China) Ltd (HCM). have?

HUTCHMED (China) Ltd (HCM) has 1811 emplpoyees as of July 08 2025.

arrow icon

What is HUTCHMED (China) Ltd (HCM) market cap?

Today HCM has the market capitalization of 2.69B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free